Search

Your search keyword '"van Erpecum, Karel J."' showing total 190 results
Start Over Author "van Erpecum, Karel J." Search Limiters Peer Reviewed
190 results on '"van Erpecum, Karel J."'

5. Increased Mortality Among Patients With vs Without Cirrhosis and Autoimmune Hepatitis

Author

Schreuder, T.C.M.A., van der Wouden, E.J., van Meyel, J.J.M., Baak, L.C., Stadhouders, P.H.G.M., Klemt-Kropp, M., Verhagen, M.A.M.T., Bhalla, A., Kuijvenhoven, J.Ph., van den Brand, Floris F., van der Veen, Koen S., de Boer, Ynto S., van Gerven, Nicole M., Lissenberg-Witte, Birgit I., Beuers, Ulrich, van Erpecum, Karel J., van Buuren, Henk R., den Ouden, Jannie W., Brouwer, Johannus T., Vrolijk, Jan M., Verdonk, Robert C., van Hoek, Bart, Koek, Ger H., Drenth, Joost P.H., Guichelaar, Marleen M.J., Mulder, Chris J.J., Bloemena, Elisabeth, van Nieuwkerk, Carin M.J., and Bouma, Gerd

Published
2019
Full Text
View/download PDF

6. Addition of PEG‐interferon to long‐term nucleos(t)ide analogue therapy enhances HBsAg decline and clearance in HBeAg‐negative chronic hepatitis B: Multicentre Randomized Trial (PAS Study).

Author

Farag, Mina S., van Campenhout, Margo J. H., Sonneveld, M. J., Fung, Scott, van Erpecum, Karel J., Wong, David K., Verhey, Elke, de Man, Robert, De Knegt, Robert J., Brouwer, Johannes T., Baak, Hubertus C., Feld, Jordan J., Liem, Kin Seng, Boonstra, André, Hansen, Bettina E., and Janssen, Harry L. A.

Subjects
CHRONIC hepatitis B, IMMUNOREGULATION
Abstract

We studied whether 48 weeks of PEG‐IFN alfa‐2a add‐on increases HBsAg‐decline and clearance in HBeAg‐negative patients on long‐term nucleo(s)tide analogue (NA) therapy. In this investigator‐initiated, randomized, controlled trial conducted in Europe and Canada, HBeAg‐negative patients treated with NA > 12 months, with HBVDNA < 200 IU/mL, were enrolled. Patients were randomized 2:1 to 48 weeks of PEG‐IFN alfa‐2a add‐on (180 μg per week) or continued NA‐monotherapy with subsequent follow‐up to Week 72. Endpoints were HBsAg decline (≥1 log10 IU/mL) and HBsAg clearance at Week 48. Of the 86 patients in the modified‐intention‐to‐treat analysis, 58 patients received PEG‐IFN add‐on, and 28 continued NA monotherapy. At Week 48, 16(28%) patients achieved HBsAg decline ≥1 log10 in the add‐on arm versus none on NA‐monotherapy (p <.001), and HBsAg clearance was observed in 6 (10%) PEG‐IFN add‐on patients versus 0% NA‐monotherapy (p =.01). HBVRNA was only detected in 2% after PEG‐IFN treatment versus 19% in NA‐monotherapy (p =.002) at Week 48. PEG‐IFN add‐on therapy was well tolerated in majority of patients. Low baseline HBsAg levels (<10 IU/mL) identified patients most likely to achieve HBsAg loss with PEG‐IFN add‐on, whereas an HBsAg level > 200 IU/mL at on‐treatment Week 12 was highly predictive of non‐response (NPV = 100%). Addition of PEG‐IFN to long‐term NA enhanced HBsAg decline and increased the chance of HBsAg clearance in HBeAg‐negative patients on long‐term NA. On‐treatment HBsAg levels >200 IU/mL identify patients unlikely to benefit from PEG‐IFN add‐on and could be used as a potential stopping‐rule for PEG‐IFN therapy. Our findings support further exploration of immune modulation add‐on to antiviral therapy, preferably using response‐guided strategies, to increase functional cure rates in patients with CHB. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

15. Health‐related quality of life in patients with primary sclerosing cholangitis: A longitudinal population‐based cohort study.

Author

Mol, Bregje, van Munster, Kim N., Bogaards, Johannes A., Weersma, Rinse K., Inderson, Akin, de Groof, E. Joline, Rossen, Noortje G. M., Ponsioen, Willemijn, Turkenburg, Maud, van Erpecum, Karel J., Poen, Alexander C., Spanier, B. W. Marcel, Beuers, Ulrich H. W., and Ponsioen, Cyriel Y.

Subjects
QUALITY of life, CHOLANGITIS, SEASONAL variations of diseases, INFLAMMATORY bowel diseases, COHORT analysis, SPRING, LIVER transplantation
Abstract

Background & Aims: Data regarding health‐related quality of life (HRQoL) in primary sclerosing cholangitis (PSC) are sparse and have only been studied cross‐sectionally in a disease which runs a fluctuating and unpredictable course. We aim to describe HRQoL longitudinally by using repeated measurements in a population‐based cohort. Methods: Every 3 months from May 2017 up to August 2020, patients received digital questionnaires at home. These included the EQ‐5D, 5‐D Itch, patient‐based SCCAI and patient‐based HBI. The SF‐36, measuring HRQoL over eight dimensions as well as a physical component summary (PCS) and mental component summary (MCS) score, was sent annually. Data were compared with Dutch reference data and a matched IBD disease control from the population‐based POBASIC cohort. Mixed‐effects modelling was performed to identify factors associated with HRQoL. Results: Three hundred twenty‐eight patients completed 2576 questionnaires. A significant reduction of small clinical relevance in several mean HRQoL scores was found compared with the Dutch reference population: 46.4 versus 48.0, p =.018 for PCS and 47.5 versus 50.5, p =.004 for MCS scores. HRQoL outcomes were significantly negatively associated with coexisting active IBD (PCS −12.2, p <.001 and MCS −12.0, p <.001), which was not the case in case of quiescent IBD. Decreasing HRQoL scores were also negatively associated with increasing age (PCS −0.1 per 10 years, p =.002), female sex (PCS ‐2.8, p <.001), diagnosis of AIH overlap (PCS ‐3.7, p =.059), end‐stage liver disease (PCS ‐3.7, p =.015) and presence of itch (PCS ‐9.2, p <.001 and MCS −3.1, p =.078). The odds of reporting a clinically relevant reduction in EQ‐5D scores showed seasonal variation, being lowest in summer (OR = 0.48 relative to spring, p =.037). In patients with liver transplant, HRQoL outcomes were comparable to the Dutch general population. Conclusions: PSC patients report impaired HRQoL of small clinical relevance compared with the general population. After liver transplantation, HRQoL scores are at comparable levels to the general population. HRQoL scores are associated with potentially modifiable factors such as itch and IBD activity. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

16. Disease burden in primary sclerosing cholangitis in the Netherlands: A long‐term follow‐up study.

Author

van Munster, Kim N., Mol, Bregje, Goet, Jorn C., van Munster, Sanne N., Weersma, Rinse K., de Vries, Annemarie C., van der Meer, Adriaan J., Inderson, Akin, Drenth, Joost P., van Erpecum, Karel J., Boonstra, Kirsten, Beuers, Ulrich, Dijkgraaf, Marcel G. W., and Ponsioen, Cyriel Y.

Subjects
CHOLANGITIS, LABOR productivity, LIVER transplantation, LIFE expectancy, MEDICAL care costs, QUALITY of life
Abstract

Background & Aims: Primary sclerosing cholangitis (PSC) is a progressive, cholestatic liver disease which greatly impacts the lives of individuals. Burden of disease due to shortened life expectancy and impaired quality of life is ill‐described. The aim of this study was to assess long‐term disease burden in a large population‐based registry with regard to survival, clinical course, quality adjusted life years (QALYs), medical consumption and work productivity loss. Methods: All PSC patients living in a geographically defined area covering ~50% of the Netherlands were included, together with patients from the three liver transplant centres. Survival was estimated by competing risk analysis. Proportional shortfall of QALYs during disease course was measured relative to a matched reference cohort using validated questionnaires. Work productivity loss and medical consumption were evaluated over time. Results: A total of 1208 patients were included with a median follow‐up of 11.2 year. Median liver transplant‐free survival was 21.0 years. Proportional shortfall of QALYs increased to 48% >25 years after diagnosis. Patients had on average 12.4 hospital contact days among which 3.17 admission days per year, annual medical costs were €12 169 and mean work productivity loss was 25%. Conclusions: Our data quantify for the first time disease burden in terms of QALYs lost, clinical events, medical consumption, costs as well as work productivity loss, and show that all these are substantial and increase over time. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

17. Systematic review with meta‐analysis: Branched‐chain amino acid supplementation in liver disease.

Author

van Dijk, Anne M., Bruins Slot, Alexandra S., Portincasa, Piero, Siegerink, Sebastiaan N., Chargi, Najiba, Verstraete, Carina J. R., de Bruijne, Joep, Vleggaar, Frank P., and van Erpecum, Karel J.

Subjects
BRANCHED chain amino acids, LIVER diseases, PARACENTESIS, AMINO acids, DIETARY supplements, ESOPHAGEAL varices, NUTRITIONAL status
Abstract

Background: Dietary supplementation with branched‐chain amino acids (BCAA) is often used in cirrhotic patients to improve nutritional status. We wanted to explore the evidence for BCAA supplementation in chronic liver disease. Methods: We searched MEDLINE and EMBASE for studies with BCAA supplementation with the presence of a disease‐control group (placebo or no intervention) using search terms 'liver cirrhosis', 'hepatocellular carcinoma', 'branched chain amino acids' and relevant synonyms. Risk of bias was assessed using ROBINS‐I and RoB 2.0 tools. Meta‐analyses were performed with a random‐effects model. Results were reported following EQUATOR guidelines. Results: Of 3378 studies screened by title and abstract, 54 were included (34 randomized controlled trials, 5 prospective case–control studies, 13 retrospective case–control studies: in total 2308 patients BCAA supplementation, 2876 disease‐controls). Risk of bias was high/serious for almost all studies. According to meta‐analyses, long‐term (at least 6 months) BCAA supplementation in cirrhotic patients significantly improved event‐free survival (p =.008; RR.61 95% CI.42–.88) and tended to improve overall survival (p =.05; RR.58 95% CI.34–1.00). Two retrospective studies suggested the beneficial effects during sorafenib for hepatocellular carcinoma. Available studies reported no beneficial effects or contradictory results of BCAA after other specific therapeutic interventions (resection or radiological interventions for hepatocellular carcinoma, liver transplantation, paracentesis or variceal ligation). No convincing beneficial effects of BCAA supplementation on liver function, nutritional status or quality of life were found. No study reported serious side effects of BCAA. Conclusions: Prophylactic BCAA supplementation appears safe and might improve survival in cirrhotic patients. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

22. Risk factors for primary sclerosing cholangitis

Author

Boonstra, Kirsten, de Vries, Elisabeth M. G., van Geloven, Nan, van Erpecum, Karel J., Spanier, Marcel, Poen, Alexander C., van Nieuwkerk, Carin M., Witteman, Ben J., Tuynman, Hans A., Naber, Anton H., Kingma, Paul J., Beuers, Ulrich, and Ponsioen, Cyriel Y.

Published
2016
Full Text
View/download PDF

23. Liver‐related complications before and after successful treatment of chronic hepatitis C virus infection in people with inherited bleeding disorders.

Author

Isfordink, Cas J., van Erpecum, Karel J., Fischer, Kathelijn, van der Valk, Paul R., van Vulpen, Lize F. D., Schutgens, Roger E. G., Arends, Joop E., and Mauser‐Bunschoten, Evelien P.

Subjects
*HEPATITIS C, *CHRONIC hepatitis C, *TREATMENT effectiveness, *HEPATITIS C virus
Abstract

Introduction: With availability of direct‐acting antivirals (DAA), most persons with inherited bleeding disorders are currently cured of hepatitis C virus (HCV) infection. The risk of liver‐related complications following HCV cure has not been reported for this population. Aim: Reporting liver‐related complications during long‐term chronic HCV infection and following sustained virological response (SVR) in this population. Methods: Retrospective follow‐up of a prospective single‐centre cohort of HCV antibody‐positive persons with inherited bleeding disorders. Primary endpoint was liver‐related complications [hepatocellular carcinoma (HCC), decompensated cirrhosis, bleeding gastroesophageal varices]. Liver‐related complications were reported separately during chronic HCV and following SVR, stratified for interferon‐based and DAA‐based SVR. Results: In total 309/381 (81%) HCV antibody‐positive individuals developed chronic HCV infection. Median follow‐up was 44 years [interquartile range (IQR): 34–50]. Liver‐related complications occurred in 36/309 (12%) of individuals with chronic HCV infection after median 31 years of chronic infection. Of 199 individuals with SVR, 97 were cured with interferon‐based regimens and 102 with DAA after median infection durations of 29 and 45 years, respectively. At end of follow‐up, respectively, 21% and 42% had advanced fibrosis or cirrhosis. Post‐SVR, seven (4%) individuals had a liver‐related complication, mainly HCC (n = 4). Incidence of liver‐related complications per 100 patient‐years post‐SVR follow‐up was.2 for interferon‐cured and 1.0 for DAA‐cured individuals (p =.01). Conclusion: Successful HCV treatment does not eliminate the risk of liver‐related complications in persons with inherited bleeding disorders. Due to higher baseline risk, incidence was higher after DAA than interferon‐based SVR. We advise continuing HCC surveillance post‐SVR in all with advanced fibrosis or cirrhosis. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

32. Serum Immunoglobulin G4 and Immunoglobulin G1 for Distinguishing Immunoglobulin G4-Associated Cholangitis From Primary Sclerosing Cholangitis

Author

Boonstra, Kirsten, Culver, Emma L., de Buy Wenniger, Lucas Maillette, van Heerde, Marianne J., van Erpecum, Karel J., Poen, Alexander C., van Nieuwkerk, Karin M.J., Spanier, Marcel B.W., Witteman, Ben J.M., Tuynman, Hans A.R.E., van Geloven, Nan, van Buuren, Henk, Chapman, Roger W., Barnes, Eleanor, Beuers, Ulrich, and Ponsioen, Cyriel Y.

Published
2014
Full Text
View/download PDF

41. Cytotoxic T Lymphocyte Antigen–4 +49A/G polymorphism does not affect susceptibility to autoimmune hepatitis

Author

van Gerven, Nicole M. F., de Boer, Ynto S., Zwiers, Antonie, van Hoek, Bart, van Erpecum, Karel J., Beuers, Ulrich, van Buuren, Henk R., Drenth, Joost P. H., den Ouden, Jannie W., Verdonk, Robert C., Koek, Ger H., Brouwer, Johannes T., Guichelaar, Maureen M. J., Vrolijk, Jan M., Kraal, G., Mulder, Chris J. J., van Nieuwkerk, Carin. M. J., and Bouma, Gerd

Published
2013
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results